Market Cap (In USD)
38.08 Million
Revenue (In USD)
-
Net Income (In USD)
-76.4 Million
Avg. Volume
144.85 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.5-1.93
- PE
- -
- EPS
- -
- Beta Value
- -0.199
- ISIN
- US98422T1007
- CUSIP
- 98422T100
- CIK
- 1840233
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Rene Russo BCPS, Pharm.D.
- Employee Count
- -
- Website
- https://www.xiliotx.com
- Ipo Date
- 2021-10-22
- Details
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
More Stocks
-
SAVA
-
600368
-
6093
-
MDNA
-
LAC
-
EMMNEmmi AG
EMMN
-
603797
-
RAMANEWSShree Rama Newsprint Limited
RAMANEWS